More than half of patients have achieved a ≥15 letter gain, with additional benefit observed at the top highest dose levels 53 Proportion of ≥15 letter gainers Patients, % 38 62 54 51 0 20 40 60 80 100 2.5 mg (n=13) 5 mg (n=13) 10 mg (n=13) All patients (n=39) Preliminary Analysis The APEX study is ongoing. Final results may be different due to additional data collection or data cleaning. Includes patients in the per protocol set that completed the Week 12 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). New Data